Skip to main content
Shire collaborates with Rani on hemophilia A drug study

Shire entered a deal with Rani Therapeutics to develop an orally delivered therapy for patients with hemophilia A using Rani's Pill technology. Under the agreement, Shire gets an exclusive licensing option to develop and commercialize the technology to deliver factor VIII treatment upon completion of feasibility studies.

Full Story: